Tetrachlorodecaoxide clinical trials
Also written DAC N-055.
How each study uses tetrachlorodecaoxide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tetrachlorodecaoxide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DAC N-055
- 2
Studies by the year they started
3 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2010 | 1 |
| 2025 | 1 |
Who runs them
Industry 0 · Other 3
Waisenmedizin e. V. Promoting Access to Essential Medicine (2) · Fazeelat Bibi (1)
Studies
Open first, then newest update. How each study uses tetrachlorodecaoxide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Efficacy of Tetrachlorodecaoxide (TCDO) Drops in Chronic Wound HealingNot yet recruitingNot applicableFazeelat BibiNCT07096830Written as Topical Tetrachlorodecaoxide (TCDO/Oxoferin)
- Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in KabulCompletedPhase 2/3Waisenmedizin e. V. Promoting Access to Essential MedicineNCT00947362Written as DAC N-055
- Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis PatientsCompletedPhase 2Waisenmedizin e. V. Promoting Access to Essential MedicineNCT00996463Written as DAC N-055
Codes
What other systems call tetrachlorodecaoxide · ClinicalTrials.gg INT003158
- UNII (FDA) 549BT7IE1QTETRACHLORODECAOXIDEOne source FDA
- NCI Thesaurus C219410TetrachlorodecaoxideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 549BT7IE1Q | TETRACHLORODECAOXIDE | One source FDA |
| NCI Thesaurus | C219410 | Tetrachlorodecaoxide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.